Keyphrases
Inflammatory Bowel Disease
100%
Crohn's Disease
84%
Tumour Necrosis Factor Inhibitor (TNFi)
27%
Perianal Crohn's Disease
25%
Ulcerative Colitis
24%
Magnetic Resonance Enterography
22%
Ustekinumab
19%
Adverse Event Reporting System
18%
Vedolizumab
17%
Computed Tomography
17%
Adverse Events
16%
Fistula
14%
Disease Activity
14%
Small Bowel Crohn's Disease
14%
Chronic Inflammatory Diseases
14%
Confidence Interval
13%
Non-alcoholic Fatty Liver Disease (NAFLD)
13%
Stricture
13%
COVID-19
12%
Pouch
12%
Thiopurines
12%
Anti-tumor Necrosis Factor (anti-TNF)
10%
Monotherapy
10%
Ischemic Colitis
10%
Immunomodulator
10%
Computed Tomography Enterography
10%
Remission
10%
United States
10%
Odds Ratio
10%
Tofacitinib
9%
Perianal Fistula
9%
Clinical Trials
9%
Crohn's Colitis
9%
Disease Severity
8%
Crohn's Disease of the Pouch
8%
Infliximab
8%
Medical Management
8%
Risk Factors
8%
Clinical Remission
8%
Bariatric Surgery
7%
Medical Therapy
7%
Response to Therapy
7%
Clinical Practice
7%
Magnetic Resonance Imaging
7%
Ileal Pouch-anal Anastomosis
7%
Vaccination
7%
Small Intestine
7%
Inflammation
7%
Radiologists
6%
Patient-reported Outcomes
6%
Medicine and Dentistry
Crohn's Disease
86%
Inflammatory Bowel Disease
63%
Diseases
31%
Patient with Inflammatory Bowel Disease
26%
Ulcerative Colitis
23%
Patient with Crohn's Disease
23%
Magnetic Resonance Enterography
22%
Fistula
19%
Disease Activity
17%
Computer Assisted Tomography
15%
Diagnosis
14%
Pouchitis
13%
Magnetic Resonance Imaging
12%
Combination Therapy
10%
Nonalcoholic Fatty Liver
10%
Ileo-Anal Pouch
9%
Computed Tomography Enterography
9%
Biological Product
9%
Anal Fistula
9%
Tumor Necrosis Factor
8%
Biological Marker
8%
Vedolizumab
8%
Cancer
8%
Systematic Review
8%
Fluorodeoxyglucose F 18
7%
Bariatric Surgery
7%
Patient-Reported Outcome
7%
Ustekinumab
7%
Stricture
7%
Disease Course
7%
TNF Inhibitor
7%
Serositis
7%
Adverse Event
7%
Endoscopy
7%
Positron Emission Tomography-Computed Tomography
6%
Biological Therapy
6%
Clinical Trial
6%
Odds Ratio
6%
Dysplasia
5%
Disease Severity
5%
Ischemic Colitis
5%
Coeliac Disease
5%
Pharmacology, Toxicology and Pharmaceutical Science
Inflammatory Bowel Disease
53%
Crohn's Disease
52%
Adverse Event
36%
Tumor Necrosis Factor Inhibitor
31%
Ulcerative Colitis
19%
Ustekinumab
15%
Remission
14%
Tumor Necrosis Factor
13%
Mercaptopurine
12%
Biological Product
12%
Diseases
11%
Combination Therapy
11%
Immunomodulating Agent
11%
Vedolizumab
10%
Inflammatory Disease
10%
Monotherapy
10%
Tofacitinib
8%
Infection
8%
Infliximab
8%
Aminosalicylic Acid
8%
Messenger RNA
7%
Rheumatoid Arthritis
6%
Inflammatory Arthritis
6%
SARS Coronavirus
6%
Disease Activity
6%
Clinical Trial
5%
Fistula
5%
Immunogenicity
5%
Ischemic Colitis
5%
Sodium Dihydrogen Phosphate
5%
Pharmacokinetics
5%